Open AccessSafety & efficacy of an intravasal, one-time injectable & non-hormonal male contraceptive (RISUG): A clinical experience
Author(s) -
Radhey Shyam Sharma,
Ajit Kumar Mathur,
Rajeev Singh,
Hem Chandra Das,
Gulshan Jeet Singh,
Devinder Pal Singh Toor,
Sujoy K. Guha
Publication year - 2019
Publication title -
indian journal of medical research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.578
H-Index - 87
ISSN - 0971-5916
DOI - 10.4103/ijmr.ijmr_635_18
Subject(s) - medicine , hormone , gynecology , clinical research , physiology , endocrinology
For improved male contraception, a new polymeric drug molecule - Reversible Inhibition of Sperm under Guidance (RISUG) has been synthesized and has been found to be effective, safe and reversible in various animal species. Phase-I and phase-II clinical trials have confirmed its safety and contraceptive efficacy. The present study was undertaken as a multicentric-limited phase-III clinical trial to test the efficacy and safety of RISUG in human volunteers.